Ibrunib 140 mg (Capsule)
Unit Price: ৳ 550.00 (1 x 60: ৳ 33,000.00)
Strip Price: ৳ 33,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibrutinib |
| Company | Jenphar bangladesh ltd |
Therapeutic Class
- Targeted Cancer Therapy
Indications
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone Lymphoma
Pharmacology
- Inhibitor of BTK
- Forms covalent bond with BTK active site
- Inhibition of BTK enzymatic activity
- Signaling molecule of the B-cell antigen receptor and cytokine receptor pathways
- Inhibits malignant B-cell proliferation and survival
- Inhibits cell migration and substrate adhesion
Dosage
- Recommended dose for Mantle Cell Lymphoma and Marginal Zone Lymphoma is 560 mg once daily
- Recommended dose for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstrom Macroglobulinemia is 420 mg once daily
- Combination dose for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with bendamustine and rituximab is 420 mg once daily
Administration
- Orally administered once daily
- Swallow capsules whole with water
Interaction
- Avoid co-administration with strong and moderate CYP3A inhibitors
- Reduce dose if co-administered with moderate CYP3A inhibitor
- Avoid co-administration with strong CYP3A inducers
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
Side Effects
- Hemorrhage
- Infections
- Cytopenias
- Atrial Fibrillation
- Hypertension
- Second Primary Malignancies
- Tumor Lysis Syndrome
- Diarrhea
- Visual Disturbance
Pregnancy & Lactation
- Can cause fetal harm based on animal studies
- Potential hazard to the fetus if used during pregnancy
- No information regarding presence in human milk or effects on breastfed infant
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- 62% of patients in clinical studies were 65 years of age or older
- 21% of patients were 75 years of age or older
- No overall differences in effectiveness between younger and older patients
- Anemia and pneumonia occurred more frequently in older patients
- Metabolized in the liver
- Safety not evaluated in cancer patients with hepatic impairment
- Not recommended for patients with moderate or severe hepatic impairment
Overdose Effects
- No specific experience in management of overdose
- Reversible Grade 4 hepatic enzyme increases observed in one subject
- Closely monitor and provide appropriate supportive treatment
Storage Conditions
- Store in a dry place below 30°C
- Protect from light
- Keep out of the reach of children